CN114667283B - (r)-n-(5-(5-异丙基-1,2,4-噁二唑-3-基)-2,3-二氢-1h-茚-1-基)-2-甲基-2h-四唑-5-甲酰胺的多晶型物 - Google Patents

(r)-n-(5-(5-异丙基-1,2,4-噁二唑-3-基)-2,3-二氢-1h-茚-1-基)-2-甲基-2h-四唑-5-甲酰胺的多晶型物 Download PDF

Info

Publication number
CN114667283B
CN114667283B CN202080059957.7A CN202080059957A CN114667283B CN 114667283 B CN114667283 B CN 114667283B CN 202080059957 A CN202080059957 A CN 202080059957A CN 114667283 B CN114667283 B CN 114667283B
Authority
CN
China
Prior art keywords
polymorph
methyl
dihydro
tetrazole
carboxamide
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CN202080059957.7A
Other languages
English (en)
Chinese (zh)
Other versions
CN114667283A (zh
Inventor
N.汤姆
D.安德森
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Cytokinetics Inc
Original Assignee
Cytokinetics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cytokinetics Inc filed Critical Cytokinetics Inc
Publication of CN114667283A publication Critical patent/CN114667283A/zh
Application granted granted Critical
Publication of CN114667283B publication Critical patent/CN114667283B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4245—Oxadiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Cardiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Hospice & Palliative Care (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
CN202080059957.7A 2019-07-17 2020-07-16 (r)-n-(5-(5-异丙基-1,2,4-噁二唑-3-基)-2,3-二氢-1h-茚-1-基)-2-甲基-2h-四唑-5-甲酰胺的多晶型物 Active CN114667283B (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201962875355P 2019-07-17 2019-07-17
US62/875,355 2019-07-17
PCT/US2020/042390 WO2021011809A1 (en) 2019-07-17 2020-07-16 Polymorphs of (r)-n-(5-(5-isopropyl-1,2,4-oxadiazol-3-yl)-2,3-dihydro-1h-inden-1-yl)-2-methyl-2h-tetrazole-5-carboxamide

Publications (2)

Publication Number Publication Date
CN114667283A CN114667283A (zh) 2022-06-24
CN114667283B true CN114667283B (zh) 2023-12-26

Family

ID=71995105

Family Applications (1)

Application Number Title Priority Date Filing Date
CN202080059957.7A Active CN114667283B (zh) 2019-07-17 2020-07-16 (r)-n-(5-(5-异丙基-1,2,4-噁二唑-3-基)-2,3-二氢-1h-茚-1-基)-2-甲基-2h-四唑-5-甲酰胺的多晶型物

Country Status (16)

Country Link
US (1) US20220274969A1 (https=)
EP (1) EP3999181B1 (https=)
JP (1) JP2022542803A (https=)
KR (1) KR20220082803A (https=)
CN (1) CN114667283B (https=)
AU (1) AU2020315433A1 (https=)
BR (1) BR112022000523A2 (https=)
CA (1) CA3144974A1 (https=)
CL (1) CL2022000089A1 (https=)
ES (1) ES2982707T3 (https=)
IL (1) IL289881A (https=)
MX (1) MX2022000498A (https=)
NZ (1) NZ784931A (https=)
PH (1) PH12022550084A1 (https=)
TW (1) TW202116764A (https=)
WO (1) WO2021011809A1 (https=)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2019144041A1 (en) 2018-01-19 2019-07-25 Cytokinetics, Inc. Dihydrobenzofuran and inden analogs as cardiac sarcomere inhibitors
JP7610985B2 (ja) 2018-06-26 2025-01-09 サイトキネティックス， インコーポレイテッド 心臓サルコメア阻害剤
JP7438148B2 (ja) 2018-06-26 2024-02-26 サイトキネティックス， インコーポレイテッド 心臓サルコメア阻害剤
WO2024179422A1 (zh) * 2023-03-02 2024-09-06 苏州科睿思制药有限公司 Aficamten的共晶及其制备方法和用途

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004064730A2 (en) * 2003-01-14 2004-08-05 Cytokinetics, Inc. Compounds, compositions and methods
WO2007078815A2 (en) * 2005-12-16 2007-07-12 Cytokinetics, Inc. Certain chemical entities, compositions, and methods

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2019144041A1 (en) * 2018-01-19 2019-07-25 Cytokinetics, Inc. Dihydrobenzofuran and inden analogs as cardiac sarcomere inhibitors

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004064730A2 (en) * 2003-01-14 2004-08-05 Cytokinetics, Inc. Compounds, compositions and methods
WO2007078815A2 (en) * 2005-12-16 2007-07-12 Cytokinetics, Inc. Certain chemical entities, compositions, and methods

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
Perturbations in skeletal muscle sarcomere structure in patients with heart failure and Type 2 diabetes: restorative effects of (-)-epicatechin rich cocoa;Pam R.Taub et al.;《Clinical Science》;第125卷(第8期);383-389 *

Also Published As

Publication number Publication date
US20220274969A1 (en) 2022-09-01
IL289881A (en) 2022-03-01
EP3999181B1 (en) 2024-05-29
CN114667283A (zh) 2022-06-24
KR20220082803A (ko) 2022-06-17
AU2020315433A1 (en) 2022-03-03
JP2022542803A (ja) 2022-10-07
NZ784931A (en) 2025-03-28
PH12022550084A1 (en) 2023-04-12
ES2982707T3 (es) 2024-10-17
CA3144974A1 (en) 2021-01-21
EP3999181A1 (en) 2022-05-25
TW202116764A (zh) 2021-05-01
MX2022000498A (es) 2022-02-03
EP3999181C0 (en) 2024-05-29
WO2021011809A1 (en) 2021-01-21
BR112022000523A2 (pt) 2022-03-03
CL2022000089A1 (es) 2022-10-07

Similar Documents

Publication Publication Date Title
CN114555590B (zh) (r)-n-(5-(5-乙基-1,2,4-噁二唑-3-基)-2,3-二氢-1h-茚-1-基)-1-甲基-1h-吡唑-4-甲酰胺的多晶型物
CN114667283B (zh) (r)-n-(5-(5-异丙基-1,2,4-噁二唑-3-基)-2,3-二氢-1h-茚-1-基)-2-甲基-2h-四唑-5-甲酰胺的多晶型物
JP7623342B2 (ja) 心臓サルコメア阻害剤の経口用製剤
CN119998292A (zh) 5-(3,4-二氟苄基)-8-((1r,4r)-4-甲基环己基)-6,9-二氧代基-2,5,8-三氮杂螺[3.5]壬烷-2-甲醛的结晶形式
RU2846046C2 (ru) Полиморфы (r)-n-(5-(5-этил-1,2,4,-оксадиазол-3-ил)-2,3-дигидро-1н-инден-1-ил)-1-метил-1н-пиразол-4-карбоксамида
HK40076616A (en) Polymorphs of (r)-n-(5-(5-ethyl-1,2,4-oxadiazol-3-yl)-2,3-dihydro-1h-inden-1-yl)-1-methyl-1h-pyrazole-4-carboxamide
HK40121580A (en) Polymorphs of (r)-n-(5-(5-ethyl-1,2,4-oxadiazol-3-yl)-2,3-dihydro-1h-inden-1-yl)-1-methyl-1h-pyrazole-4-carboxamide
HK40075684A (en) Polymorphs of (r)-n-(5-(5-ethyl-1,2,4-oxadiazol-3-yl)-2,3-dihydro-1h-inden-1-yl)-1-methyl-1h-pyrazole-4-carboxamide
HK40125944A (zh) 5-(3，4-二氟苄基)-8-((1r，4r)-4-甲基环己基)-6，9-二氧代基-2，5，8-三氮杂螺[3.5]壬烷-2-甲醛的结晶形式
HK40111816A (zh) 多晶型物
HK40077275A (en) Cardiac sarcomere inhibitor oral formulations

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
GR01 Patent grant
GR01 Patent grant